Filing step-change
INDOAMIN · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-21 · Evidence medium
INDOAMIN's 34.39% gross margin accelerated to, up from 12.41%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 34.39 % | 12.41 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 12.41 % | 6.52 | ▲ |
| REVENUE_GROWTH_YOY | 30.3 % | 6.1 | ▲ |
Cite this
Source: Samhati filing step-change for INDOAMIN (2026-10). Observation: INDOAMIN's 34.39% gross margin accelerated to, up from 12.41%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/indoamin/q/2026-10
Other periods